Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: April 17, 2025
Melanoma
is
highly
invasive
and
resistant
to
conventional
treatments,
accounting
for
nearly
75%
of
skin
cancer-related
deaths
globally.
Traditional
therapies,
such
as
chemotherapy
immunotherapy,
often
exhibit
limited
efficacy
are
associated
with
significant
side
effects
due
systemic
drug
exposure.
Microneedles
(MNs),
an
emerging
delivery
system,
offer
multiple
advantages,
including
safety,
painlessness,
minimal
invasiveness,
controlled
release.
Among
these,
hydrogel
microneedles
(HMNs)
stand
out
their
extracellular
matrix-like
structure
swelling-induced
continuous
channels,
which
enable
the
direct
therapeutic
agents
into
tumor
microenvironment
(TME).
This
approach
enhances
bioavailability
while
reducing
toxicity,
establishing
HMNs
a
promising
platform
melanoma
treatment.
review
highlights
recent
advancements
in
therapy,
focusing
on
applications
biomarker
extraction
early
diagnosis
role
supporting
multimodal
treatment
strategies,
chemotherapy,
phototherapy,
targeted
combination
therapy.
Furthermore,
current
matrix
materials
fabrication
techniques
discussed.
Finally,
limitations
critically
analyzed,
recommendations
future
research
development
provided.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: Dec. 13, 2023
With
the
development
and
regulatory
approval
of
immune
checkpoint
inhibitors
adoptive
cell
therapies,
cancer
immunotherapy
has
undergone
a
profound
transformation
over
past
decades.
Recently,
therapeutic
vaccines
have
shown
promise
by
eliciting
de
novo
T
responses
targeting
tumor
antigens,
including
tumor-associated
antigens
tumor-specific
antigens.
The
objective
was
to
amplify
diversify
intrinsic
repertoire
cells.
However,
complete
realization
these
capabilities
remains
an
ongoing
pursuit.
Therefore,
we
provide
overview
current
landscape
in
this
review.
range
antigen
selection,
delivery
systems
strategic
nuances
underlying
effective
presentation
pioneered
vaccine
design.
Furthermore,
review
addresses
status
clinical
trials
discusses
their
strategies,
focusing
on
immunogenicity
anti-tumor
efficacy
assessment.
attempts
toward
developing
not
yielded
breakthrough
outcomes
due
significant
challenges,
microenvironment
suppression,
optimal
candidate
identification,
response
evaluation,
manufacturing
acceleration.
field
is
poised
overcome
hurdles
improve
patient
future
acknowledging
complexities
persistently
striving
surmount
inherent
constraints.
Journal of Hematology & Oncology,
Journal Year:
2025,
Volume and Issue:
18(1)
Published: Jan. 13, 2025
The
tumor
microenvironment
(TME)
is
integral
to
cancer
progression,
impacting
metastasis
and
treatment
response.
It
consists
of
diverse
cell
types,
extracellular
matrix
components,
signaling
molecules
that
interact
promote
growth
therapeutic
resistance.
Elucidating
the
intricate
interactions
between
cells
TME
crucial
in
understanding
progression
challenges.
A
critical
process
induced
by
epithelial-mesenchymal
transition
(EMT),
wherein
epithelial
acquire
mesenchymal
traits,
which
enhance
their
motility
invasiveness
progression.
By
targeting
various
components
TME,
novel
investigational
strategies
aim
disrupt
TME's
contribution
EMT,
thereby
improving
efficacy,
addressing
resistance,
offering
a
nuanced
approach
therapy.
This
review
scrutinizes
key
players
emphasizing
avenues
therapeutically
components.
Moreover,
article
discusses
implications
for
resistance
mechanisms
highlights
current
toward
modulation
along
with
potential
caveats.
Cancer Treatment Reviews,
Journal Year:
2025,
Volume and Issue:
133, P. 102884 - 102884
Published: Jan. 13, 2025
Breast
cancer
is
the
second
most
commonly
diagnosed
in
women
and
fifth
leading
cause
of
cancer-related
deaths
worldwide.
It
a
highly
heterogeneous
disease,
consisting
multiple
subtypes
that
vary
significantly
clinical
characteristics
survival
outcomes.
Triple-negative
breast
(TNBC)
particularly
aggressive
challenging
subtype
cancer.
Several
immunotherapeutic
approaches
have
been
tested
patients
with
TNBC
to
improve
disease
outcomes,
including
administration
dendritic
cell
(DC)-based
vaccines.
DCs
are
population
play
crucial
role
bridging
innate
adaptive
immune
systems.
Therefore,
increasingly
used
vaccines
due
their
ability
prime
boost
antigen
specific
T-cell
responses.
This
review
aims
provide
comprehensive
overview
TNBC,
potential
targets
pharmacological
strategies,
as
well
an
relevance
TNBC.
In
addition,
we
ongoing
trials
shed
light
on
evolving
landscape
DC-based
immunotherapy
for
Cell Death Discovery,
Journal Year:
2023,
Volume and Issue:
9(1)
Published: Nov. 24, 2023
Abstract
MicroRNAs
(miRNAs)
are
a
class
of
non-coding
RNAs
(ncRNAs)
with
short
length
19–22
nucleotides.
miRNAs
posttranscriptional
regulators
gene
expression
involved
in
various
biological
processes
like
cell
growth,
apoptosis,
and
angiogenesis.
miR-184
is
well-studied
miRNA,
for
which
most
studies
report
its
downregulation
cancer
cells
tissues
experiments
support
role
as
tumor
suppressor
inhibiting
malignant
behaviors
vitro
vivo.
To
exert
functions,
affects
some
signaling
pathways
tumorigenesis
Wnt
β-catenin,
AKT/mTORC1
pathway,
oncogenic
factors
(e.g.,
c-Myc)
or
apoptotic
proteins,
such
Bcl-2.
Interestingly,
clinical
investigations
have
shown
good
performance
prognostic/diagnostic
biomarker
cancers.
Additionally,
exogenous
xenograft
animal
suggest
it
therapeutic
anticancer
target.
In
this
review,
we
outline
the
that
evaluated
roles
well
significance.
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(3), P. 699 - 699
Published: March 21, 2024
Immunotherapy
using
dendritic
cell-based
vaccination
is
a
natural
approach
the
capabilities
and
functions
inherent
in
patient’s
immune
system
to
eliminate
tumor
cells.
The
development
of
cell
technologies
evolved
as
disorders
differentiation
function
cancer
were
studied;
some
these
are
antigen
presentation,
priming
cytotoxic
T-lymphocytes
induction
antigen-specific
responses.
At
initial
stage
technology
development,
it
was
necessary
develop
protocols
for
vitro
generation
functionally
mature
cells
that
capable
capturing
antigens
processing
presenting
them
complex
with
MHC
T-lymphocytes.
To
achieve
this,
various
forms
tumor-associated
delivery
systems
tested,
including
lysates,
proteins
(peptides),
DNA
RNA
constructs,
shown
use
constructs
most
effective
method,
made
possible
not
only
deliver
immunogenic
epitopes
cells,
but
also
enhance
their
ability
induce
Currently,
therapy
based
on
modern
basis
immunotherapy
due
simplicity
creating
encoding
information
about
both
target
regulatory
molecules.
potential
aims
obtain
induced
by
study
functional
activity
therapy.
Molecular Aspects of Medicine,
Journal Year:
2024,
Volume and Issue:
101, P. 101324 - 101324
Published: Dec. 3, 2024
This
review
provides
a
comprehensive
overview
of
the
evolving
landscape
cancer
vaccines,
highlighting
their
potential
to
revolutionize
tumor
prevention.
Building
on
success
vaccines
against
virus-related
cancers,
such
as
HPV-
and
HBV-associated
cervical
liver
current
challenge
is
extend
these
achievements
prevention
non-viral
tumors
treatment
preneoplastic
or
early
neoplastic
lesions.
analyzes
critical
aspects
preventive
anti-cancer
vaccination,
focusing
choice
target
antigens,
development
effective
vaccine
platforms
technologies,
use
various
model
systems
for
preclinical
testing,
from
laboratory
rodents
companion
animals.
